ADMA Biologics
ADMA
214 hedge funds and large institutions have $1.16B invested in ADMA Biologics in 2024 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 86 increasing their positions, 53 reducing their positions, and 19 closing their positions.
3,163% more call options, than puts
Call options by funds: $3.04M | Put options by funds: $93K
168% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 19
62% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 53
51% more capital invested
Capital invested by funds: $765M → $1.16B (+$391M)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
16% more funds holding
Funds holding: 184 → 214 (+30)
1.88% more ownership
Funds ownership: 74.86% → 76.74% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Ophir Asset Management
Sydney,
Australia
|
+$18.7M |
| 2 |
MIIM
Mesirow Institutional Investment Management
Chicago,
Illinois
|
+$14.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$9.25M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$9.17M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$6.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$31.7M |
| 2 |
JFG
Jefferies Financial Group
New York
|
-$10.5M |
| 3 |
Millennium Management
New York
|
-$9.52M |
| 4 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$8.87M |
| 5 |
D.E. Shaw & Co
New York
|
-$6.19M |
ADMA Hedge Fund Activity: Q1 2024 in Review
214 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2024, worth a combined $1.16B — up 51% from $765M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new ADMA positions and 19 closed out — a net gain of 32 holders — while 86 added to existing stakes and 53 trimmed.
The largest buyer was Ophir Asset Management, opening a new position worth an estimated $18.7M. The largest seller was Stonepine Capital Management, cutting an estimated $31.7M.
- 214 institutional investors held ADMA Biologics (ADMA) as of Q1 2024, up from 184 in Q4 2023.
- Funds reported $1.16B of ADMA Biologics stock for Q1 2024, up 51% quarter-over-quarter.
- 51 funds opened new ADMA Biologics positions in Q1 2024 and 19 closed out, a net change of +32 holders.
- The largest ADMA Biologics buyer in Q1 2024 was Ophir Asset Management, an estimated $18.7M added.
- The largest ADMA Biologics seller in Q1 2024 was Stonepine Capital Management, an estimated $31.7M sold.
Based on aggregated 13F filings for Q1 2024.